Zolimomab aritox

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Zolimomab aritox
Monoclonal antibody
TypeWhole antibody
Clinical data
ATC code
  • none
CAS Number
  • none
 ☒N☑Y (what is this?)  (verify)

Zolimomab aritox is a mouse monoclonal antibody which has been investigated for the treatment of systemic lupus erythematosus[1] and graft-versus-host disease,[2] but the studies failed to show positive effects of the drug.

It is an anti-CD5 antibody which is linked to the A chain of the ricin protein (which is reflected by the aritox in the drug's name).[3]

See also[edit]


  1. ^ Stafford, FJ; Fleisher, TA; Lee, G; Brown, M; Strand, V; Austin Ha, 3rd; Balow, JE; Klippel, JH (1994). "A pilot study of anti-CD5 ricin a chain immunoconjugate in systemic lupus erythematosus". The Journal of Rheumatology. 21 (11): 2068–70. PMID 7532717.
  2. ^ Przepiorka, D; Lemaistre, CF; Huh, YO; Luna, M; Saria, EA; Brown, CT; Champlin, RE (1994). "Evaluation of anti-CD5 ricin a chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation". Therapeutic immunology. 1 (2): 77–82. PMID 7584486.
  3. ^ WHO Drug Information